Aromatase Inhibitors in the Treatment of Male Infertility

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Obesity, Oligospermia

In brief

Obesity is associated with an increase in blood levels of estrogen. Estrogen or "female hormone" is believed to have a negative effect on sperm production. Aromatase inhibitors such as anastrozole work to decrease the production of estrogen and increase testosterone in the body. By decreasing the level of estrogen, sperm production should improve. In this study, the investigators will try to determine the benefit of anastrozole in obese men and follow pregnancy outcomes.

Key facts

Study ID

NCT00440180

Run by

University of Utah

People needed

20

Starts

2007-03-01

Expected to finish

2014-06-01

Last updated by the study team

2016-04-06

Who can join

Age: 16 and older, up to 80. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Male partner of a couple presenting for infertility work up after one year of unprotected intercourse
• Moderate oligozoospermia (defined as mean sperm count ≤ 20 × 106/mL and ≥ than 3 × 106/mL) of at least two separate occasions spanning a minimum of two weeks
• Obese men BMI ≥ 30
• FSH and LH levels < 10 mIU/mL

You may not qualify if…

• Severe Oligozoospermia: Sperm count < than 3 × 106/mL, including azoospermia
• Age less than 18 or greater than 65 years
• Pyospermia or leukospermia: defined by white blood cells ≥ 1 million leukocytes per milliliter of semen
• Cryptorchidism
• Vasectomy reversal
• Regular use of tobacco products
• BMI < 30
• Use of anabolic steroids or testosterone replacement
• All patients with abnormal initial liver function tests "AST or ALT" will be excluded form the study

Where it is running

• University of Utah — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.